Oral curcumin or curcuminoid supplementation × Reduction of systolic blood pressure in adults with metabolic risk

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionWhich systolic-blood-pressure question is addressed?Required	The original question concerns systolic-blood-pressure reduction in adults with metabolic risk, with office SBP as the endpoint. Medicine replacement and other endpoints are excluded. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Oral curcumin/curcuminoid supplementation and office SBP change in adults with metabolic risk	Material needed: Original eligibility criteria and endpoint tables specifying the same population, formulation, comparator and office SBP are needed. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionWhich formulations were pooled, and do they match individual products?Required	The retained formulation is mixed oral products. The product notes do not treat conventional curcumin, nano/micellar, phytosomal, piperine-combination and topical products as equivalent. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original-trial tables separating conventional curcumin, nano/micellar, phytosomal and piperine-combination formulations	Material needed: Actual formulations, absorption enhancers, standardized amounts and product information for included trials are unavailable; efficacy or equivalence of an individual product is not established. This records needed materials; no new research was executed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionWhich doses and administration frequencies were compared?Required	Doses vary by trial. Representative doses, conversions of total product amounts to active amounts and recommended doses are not generated. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial-specific active-curcumin/curcuminoid amounts, total product amounts and administration frequencies	Material needed: Original amount/dose/adherence tables are needed. The phrase dose response in the meta-analysis title does not establish an optimum dose. This records needed materials; no new research was executed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionHow are duration and outcome timepoints arranged?Required	Durations vary by trial, with some at least 12 weeks. The overall pooled estimate is not labeled as an estimate restricted to trials lasting at least 12 weeks. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial-specific exposure durations and final SBP timepoints	Material needed: Trial-specific durations, measurement schedules and original extracted values by duration group are needed. Long-term persistence and post-discontinuation effects remain unverified. This records needed materials; no new research was executed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionDo the included adults share the same risks and diagnoses?Required	The population includes adults with hypertension, prehypertension or metabolic risk. It is not relabeled as a single hypertensive population. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Composition by diagnosis/baseline risk among adults with hypertension, prehypertension or metabolic risk	Material needed: Original-trial tables by diagnosis, baseline SBP, age, comorbidities and eligibility/exclusion criteria are needed. This records needed materials; no new research was executed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionWas the comparator placebo or control management?Required	The comparator is placebo or control management. Identical placebo and lifestyle-care arrangements across all trials are not established. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial-specific placebo/control management and common-care arrangements	Material needed: Trial-specific material separating placebo ingredients, blinding, shared dietary/exercise management and additional interventions is needed. This records needed materials; no new research was executed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionHow do concomitant blood-pressure medicines and lifestyle management differ?Required	The original precaution says curcumin does not replace blood-pressure medicines and possible hypotension/interactions during concomitant use require individual review. Included-trial co-treatment arrangements are absent from the summary. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Baseline blood-pressure medicines, changes, diet/exercise management and whether these were shared across groups	Material needed: Original-trial records on medicine doses/changes, lifestyle management, rescue medicines and adherence are needed. Efficacy is not separated as the supplement-only effect. This records needed materials; no new research was executed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionWhat included-material unit does the reported 17 represent?Required	The research description says mean differences from 17 trials were pooled; the evidence scope says 17 studies and 1,377 people. Original wording is retained without certifying 17 unique trials here. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Review inclusion lists and study-to-report links	Material needed: Links among included articles, registrations, duplicate reports and multiple arms are needed. Reported scope remains distinct from verified unique-trial counts. This records needed materials; no new research was executed.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionWhat denominator does 1,377 people represent?Required	1,377 people is the original reported scope. Group-specific allocation, analysis, completion and SBP analysis denominators are not generated. Unique-participant totals remain unverified. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial-specific allocation, analysis, completion and SBP-endpoint denominators	Material needed: Trial/group-specific randomized, analyzed and completed denominators, with participant-overlap information, are needed. The final unique-participant total remains null. This records needed materials; no new research was executed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionCan review reports be linked to original-trial families?Required	The structured report is a single review by Hadi and colleagues. One review report remains distinct from counts of original trials and independent teams. Original-trial families/overlap remain unverified. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Included-trial identifiers and study-family links for the Hadi review	Material needed: Articles, registrations and additional reports for included trials, with the review extraction table, are needed. Shared trials and reused samples remain unverified. This records needed materials; no new research was executed.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionIn which units is the overall SBP effect reported?Required	The overall result is WMD −0.06 mmHg, 95% CI −0.62 to 0.50, P=.85; I²=44.2%. The numbers are retained without new conversion or pooling. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Overall office-SBP WMD, units and original comparison arrangements	Material needed: Original pooling tables, extracted values, weights, analysis models and change/final-value distinctions are needed. New estimates, conversions and clinical numerical calculations are not produced. This records needed materials; no new research was executed.
12	Partly verified	Full text not readStored summary read	N12 · Evidence conditionWhat is the scope of the original CI and null interpretation?Required	The original reader answer describes a clear null result, and the key rationale says the entire CI lies within 1 mmHg. Those original verdict statements are retained without new equivalence/null certification. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original 95% CI and source of SBP-importance criteria	Material needed: Unread original analysis tables and prespecified importance/equivalence criteria are needed. Equivalence for all formulations/populations or a new D verdict is not certified here. This records needed materials; no new research was executed.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionHow are I² and between-trial differences retained?Required	I²=44.2% is an original value. The counterview retains possible post hoc subgrouping and heterogeneity. This number does not establish identical formulations, populations or durations. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Overall heterogeneity and explanations by formulation, diagnosis, dose and duration	Material needed: Original heterogeneity tables, extracted values, model/sensitivity analyses and prediction intervals are needed. I² alone does not establish equal results across formulations. This records needed materials; no new research was executed.
14	Partly verified	Full text not readStored summary read	N14 · Evidence conditionIs office SBP measurement distinguished from other blood-pressure measures?Required	The selected endpoint is office systolic-blood-pressure change. It is not replaced with ambulatory/home blood pressure or DBP. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Office-SBP equipment, repetitions, timing, assessors and original endpoint definitions	Material needed: Trial-specific measurement procedures, assessor blinding and repeated-measurement/averaging rules are needed. This records needed materials; no new research was executed.
15	Partly verified	Full text not readStored summary read	N15 · Evidence conditionAre change values, baseline adjustment and analysis timepoints aligned?Required	The selected endpoint describes SBP change, while the research description says mean differences were pooled. Detailed arrangements for change/final values, adjustment and timepoint selection remain unverified. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	SBP change versus final/baseline-adjusted values and intended analysis populations	Material needed: Original extraction tables, analysis plans, baseline values, variance handling, endpoint timepoints and duplicate-timepoint selection rules are needed. This records needed materials; no new research was executed.
16	Unverified	Full text not readStored summary read	N16 · Evidence conditionWhat is known about allocation and blinding in original trials?Required	The retained design is a systematic review and dose-response meta-analysis. Adequacy of original-trial allocation, concealment and blinding is not judged here. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial-specific randomization, concealment and participant/assessor blinding	Material needed: Original-trial methods, registration/protocols and the review's individual risk-assessment bases are needed. Official RoB2 findings are not generated. This records needed materials; no new research was executed.
17	Unverified	Full text not readStored summary read	N17 · Evidence conditionWhat is known about attrition, missingness and outcome selection?Required	The stored sample description gives overall scope without specific group-level attrition, missingness or analysis-exclusion reasons. Unread original material is not relabeled as having no missingness. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial-specific attrition reasons, missing-data handling, analysis sets and selective reporting	Material needed: Group flow diagrams, analysis denominators, missing-data handling, all SBP timepoints and registration-to-report comparisons are needed. This records needed materials; no new research was executed.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionIs the prespecified hierarchy of overall SBP and subgroups verified?Required	The original explanation says signals in women or trials lasting at least 12 weeks do not replace the overall SBP main result. The counterview retains possible post hoc subgrouping. Prespecification remains unverified. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Prespecified overall-SBP analysis and women/duration subgroup plans	Material needed: Review registration, protocols/SAPs with primary-endpoint/subgroup/multiplicity plans, and original-trial prespecified endpoint hierarchies, are needed. This records needed materials; no new research was executed.
19	Partly verified	Full text not readStored summary read	N19 · Evidence conditionAre signals in women distinguished from the overall adult effect?Supplementary	The original explanation mentions a signal in women. The structured evidence contains no women-only effect, CI or denominator. The overall WMD is not copied as an individual women-subgroup estimate. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Women-subgroup effects, intervals, denominators and interaction tests	Material needed: Original sex-subgroup tables, prespecification, interactions and included-trial counts are needed. The overall −0.06 mmHg is not copied as a women-only estimate. This records needed materials; no new research was executed.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionAre signals in the subgroup lasting at least 12 weeks distinguished from all durations?Supplementary	Some durations of at least 12 weeks and the corresponding subgroup signal are described. The structured overall result is not relabeled as an individual long-duration estimate or persistent effect. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial composition, effects, intervals and denominators for durations of at least 12 weeks versus shorter durations	Material needed: Original duration-group tables, prespecification, other formulation/population differences accompanying duration, and interaction material are needed. This records needed materials; no new research was executed.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionIs a DBP reduction kept from becoming an SBP success?Supplementary	Possible DBP reductions are a separate-analysis narrative in the counterview; the verdict-scope note says only SBP was graded. DBP results are not transferred into SBP success. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Separate SBP/DBP endpoints, denominators and timepoints	Material needed: Original DBP results and endpoint hierarchy address a separate question. DBP estimates and grades are not merged into these SBP rows. This records needed materials; no new research was executed.
22	Partly verified	Full text not readStored summary read	N22 · Evidence conditionAre mechanistic endpoints such as endothelial function kept separate?Supplementary	The verdict-scope note separates DBP and endothelial function. Endothelial/mechanistic improvement is not relabeled as this office-SBP result or a clinical-event effect. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing endothelial function/biomarkers from SBP change	Material needed: Separate definitions, trials and original results for mechanistic endpoints are needed. Mechanistic improvement is not relabeled as an SBP or clinical-event effect. This records needed materials; no new research was executed.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionDoes dose-response meta-analysis establish direct dose comparisons?Supplementary	The original design is a dose-response meta-analysis. Actual direct dose-comparison and optimum-dose results are absent from the stored summary. The name dose response does not establish a recommended amount. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing within-trial direct dose comparisons from between-trial dose-response models	Material needed: Trial-specific doses, effects, covariates, model/sensitivity analyses and direct dose trials are needed. This records needed materials; no new research was executed.
24	Partly verified	Full text not readStored summary read	N24 · Evidence conditionIs independent replication within a formulation verified separately?Required	The original grading rationale describes a precise synthesis across multiple independent studies. Included trials and independent teams are not certified here or promoted into formulation-specific replication. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Unique trials and independent teams sharing formulation, population, comparator and timepoint	Material needed: Original included-trial links, funding/authors and product information are needed. Mixed-formulation pooling alone does not establish independent replication for a particular formulation. This records needed materials; no new research was executed.
25	Partly verified	Full text not readStored summary read	N25 · Evidence conditionAre clinical events and replacement of blood-pressure medicines separate questions?Supplementary	The advertising limits say claims of replacing blood-pressure medicines or treating hypertension contradict the evidence. The current endpoint is SBP change, not direct results on clinical events or medicine replacement. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Direct material distinguishing an SBP surrogate from cardiovascular events and stopping/replacing medicines	Material needed: Direct research on cardiovascular events or stopping/replacing medicines is not verified in this material. Prevention, treatment or replacement effects are not added here. This records needed materials; no new research was executed.
26	Partly verified	Full text not readStored summary read	N26 · Evidence conditionAre four routes of company involvement kept separate?Required	The funding description says non-commercial researchers and mixed funding of included trials. The English funding wording is a generic statement distinguishing involvement routes. This is not relabeled as absence of company involvement in all trials. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Review/trial funding, product support, employee authorship and COI	Material needed: Original funding, product provision, author affiliations and COI disclosures for the review and original trials are needed. Non-commercial researchers do not establish absence of company involvement in every trial. This records needed materials; no new research was executed.
27	Unverified	Full text not readStored summary read	N27 · Evidence conditionAre harm-collection methods known?Supplementary	The original safety detail retains caution and possible hypotension/interactions during concomitant use. Harm-collection methods and event tables are not preserved in detail. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Adverse-event definitions, active/passive collection, durations and group-specific classification	Material needed: Included-trial harm methods, event tables, withdrawals and severity records are needed. Unread material is not labeled as no harm. This records needed materials; no new research was executed.
28	Unverified	Full text not readStored summary read	N28 · Evidence conditionWhat are harm denominators and exposure durations?Supplementary	1,377 people describes the evidence scope, not a safety denominator. Durations also vary by trial. Group-specific event counts, exposure and harm denominators remain unverified. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Group-specific safety denominators, actual dosing, exposure durations and harm analyses	Material needed: Safety sets, exposure amounts/time, group-specific event counts and discontinuation records are needed. Incidence is not calculated. This records needed materials; no new research was executed.
29	Partly verified	Full text not readStored summary read	N29 · Evidence conditionWhat evidence level underlies concomitant hypotension/interaction precautions?Supplementary	The original wording is a precaution requiring individual review of concomitant use. It is not actual hypotension incidence, established causation or a direct interaction comparison. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Concomitant blood-pressure medicines, event timing, alternative causes and direct comparisons	Material needed: Medicine types/changes, event timing, comparators, rechallenge and alternative-cause material are needed. This records needed materials; no new research was executed.
30	Unverified	Full text not readStored summary read	N30 · Evidence conditionAre long-term, rare-event and vulnerable-population harms verified?Supplementary	Mixed durations and precautions alone do not certify long-term, rare-event or vulnerable-population safety, or independent harm replication. Corresponding original material remains unverified. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Harm material on long exposure, rare events and vulnerable populations	Material needed: Long-term follow-up, vulnerable populations, independent harm reports and exposure/denominators are needed. These harms are not newly investigated or established here. This records needed materials; no new research was executed.
31	Partly verified	Full text not readStored summary read	N31 · Evidence conditionIs actual reading scope distinguished from original-source links?Required	The full stored record was read for preparation. The original PubMed URL is linked, while external abstracts, full texts, registration and protocols/SAPs remain unread in this work. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing stored summary, abstract, full text, registration and protocols/SAPs	Material needed: External original material remains unread until acquired and reviewed. A URL does not establish reading, accessibility or fulfillment of conditions. This records needed materials; no new research was executed.
32	Partly verified	Full text not readStored summary read	N32 · Evidence conditionHow are historical English corrections and remaining generic wording retained?Supplementary	The correction records replacement of English placeholders while retaining grade, score, citations and evidence date. Remaining generic English sample, funding and result wording is preserved in the original; historical correction targets and external English material are not newly reviewed. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original Korean/English material and targets/limits of the 2026-09-14 correction	Material needed: Historical corrected English and external papers are not newly compared here. The original correction is not relabeled as completed current content QA or certified original-paper reading. This records needed materials; no new research was executed.
33	Partly verified	Full text not readStored summary read	N33 · Evidence conditionAre original grade, axes, dates and new preparation distinguished?Required	The original D/30/Caution, evidence date 2026-09-08, axes and correction are retained. Preparation is not a new efficacy grade or independent clinical certification; the original date is not relabeled as a current search-end or external-reading date. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original D30, Caution, axes, evidence date and correction	Material needed: New material and verdict changes are handled through separate review and events. The original verdict date is not relabeled as a current search-end or external-reading date. This records needed materials; no new research was executed.

No items match your search or filter.

33 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-09-08
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: Original material-specific dates are retained. The stored-summary production timestamp on 2026-10-06 is not an external-reading date; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
Population: The retained population mixes adults including hypertension, prehypertension or metabolic risk. It is not a single hypertensive population; composition and contributing denominators by diagnosis, baseline SBP, age and comorbidities remain incompletely verified.
Ingredient, formulation and route: The record covers mixed oral curcumin/curcuminoid formulations. Conventional, nano/micellar, phospholipid phytosomal, piperine-combination and topical products remain distinct; product-specific efficacy or formulation equivalence is not established.
Dose: The original record describes trial-specific doses. Total product amounts, active amounts, frequency, adherence and direct dose comparisons remain unverified; a single recommended or optimum dose is not generated.
Comparator: The retained comparator is placebo or control management. Placebo ingredients, lifestyle management, maintenance/changes of blood-pressure medicines, rescue medicines and adherence remain incompletely verified. Combined effects are not assigned to curcumin alone or replacement of blood-pressure medicines.
Measured outcome: The selected endpoint is change in office systolic blood pressure (SBP). Change/final values, baseline adjustment and measurement arrangements remain distinct. Ambulatory/home blood pressure, DBP, endothelial function and cardiovascular events address different questions.
Duration: Durations vary by trial, with some at least 12 weeks. The overall pooled estimate is not relabeled as an estimate restricted to the at least 12 week subgroup, long-term persistence or a post-discontinuation effect.
Questions outside this scope: The original D/30/Caution and B/S/RX/I2/E0/B2/C0 are retained. Historical cross-checking, independence and generic English verification wording are not inherited as current original-source reading or independent clinical validation.; The overall WMD −0.06 mmHg, 95% CI −0.62 to 0.50, P=.85; I²=44.2% is retained unchanged. No new conversion, pooling, subgroup difference or clinical numerical result is calculated.; The original interpretation of a clear null result and the entire CI lying within 1 mmHg is retained. It is not extended to a universal clinical-importance threshold, equivalence, no effect for every formulation/population or certification of a new verdict.; Signals in women, the at least 12 week subgroup and DBP are original qualitative narratives. Their effects, intervals, denominators, prespecification and interactions remain unverified; the overall SBP estimate is not copied to individual subgroups.; 17 studies and 1,377 people describe the original review's reported scope. Unique trials, participants, group-specific analysis denominators and independent teams are not certified here; reports and samples are not summed or newly established as independent replication.; The name dose-response meta-analysis does not establish direct dose-comparison or optimum-dose results. I²=44.2% also does not establish identical effects across formulations, populations or durations, or equivalence of individual products.; Original precautions against replacing blood-pressure medicines, and for individual review of possible hypotension/interactions during concomitant use, are retained. Actual harm collection, event counts, exposure/denominators, causality, direct interactions and long-term safety remain unverified.; The original evidence date 2026-09-08, correction of 1 English field on 2026-09-14 and stored-summary production date 2026-10-06 remain distinct. Production timestamps are not completed external-reading/content-review dates; actual review dates remain unrecorded.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · 2023 · Systematic review and dose-response meta-analysis of curcumin and blood pressure

PubMed

Material type: Stored description of a systematic review and dose-response meta-analysis; external methods, searches and inclusion tables remain unread
Materials actually read: Stored existing review summary read; external material unread
Findings recorded in the stored summary: WMD −0.06 mmHg, 95% CI −0.62~0.50, P=.85; I²=44.2%
Record level: This is the stored pooled difference for overall office SBP. It remains distinct from women/duration subgroups and DBP results, and is not external verification of original analyses, denominators or timepoints, or a new calculation.
Study overlap and independent replication: One review report remains distinct from its reported scope of 17 studies and 1,377 people. Overlap and unique counts of original trials, additional reports and participants, and independent teams, remain unverified; final unique-trial/participant totals are not generated.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Existing stored summary acquired	Stored summary	Stored summary read	The stored report/citation summary was read. This does not record possession or full-text reading of the external original article. Only the stored summary and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. The stored-summary production timestamp on 2026-10-06 is not an external-reading date; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
External abstract · Original PubMed link	Original bibliography link only; external content unread	Unread; no access attempt	Unread	Only the original PubMed URL is linked. Actual abstract reading, accessibility and bibliographic-content verification remain incomplete. Only the stored summary and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. The stored-summary production timestamp on 2026-10-06 is not an external-reading date; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
External full text · Unacquired/unread	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original full texts, supplements, included trials and result tables remain unacquired/unread. Abstracts or summaries are not relabeled as full-text reading. Only the stored summary and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. The stored-summary production timestamp on 2026-10-06 is not an external-reading date; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
Review/original-trial registration material	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Actual registration identifiers, contents, amendments and original-trial alignment remain unverified. Prespecification of articles/plans is not certified. Only the stored summary and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. The stored-summary production timestamp on 2026-10-06 is not an external-reading date; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
Protocols and statistical analysis plans	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original protocols, analysis plans, endpoint hierarchy, timepoints, multiplicity and attrition-handling rules remain unread. Only the stored summary and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. The stored-summary production timestamp on 2026-10-06 is not an external-reading date; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.

Report counts versus independent study counts

One review report remains distinct from its reported scope of 17 studies and 1,377 people. Overlap and unique counts of original trials, additional reports and participants, and independent teams, remain unverified; final unique-trial/participant totals are not generated.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which systolic-blood-pressure question is addressed?

Required materials and conditions: Oral curcumin/curcuminoid supplementation and office SBP change in adults with metabolic risk
Conditions for verification: Original records on Oral curcumin/curcuminoid supplementation and office SBP change in adults with metabolic risk must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Oral curcumin/curcuminoid supplementation and office SBP change in adults with metabolic risk is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N02 · Which formulations were pooled, and do they match individual products?

Required materials and conditions: Original-trial tables separating conventional curcumin, nano/micellar, phytosomal and piperine-combination formulations
Conditions for verification: Original records on Original-trial tables separating conventional curcumin, nano/micellar, phytosomal and piperine-combination formulations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Original-trial tables separating conventional curcumin, nano/micellar, phytosomal and piperine-combination formulations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N03 · Which doses and administration frequencies were compared?

Required materials and conditions: Trial-specific active-curcumin/curcuminoid amounts, total product amounts and administration frequencies
Conditions for verification: Original records on Trial-specific active-curcumin/curcuminoid amounts, total product amounts and administration frequencies must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Trial-specific active-curcumin/curcuminoid amounts, total product amounts and administration frequencies is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N04 · How are duration and outcome timepoints arranged?

Required materials and conditions: Trial-specific exposure durations and final SBP timepoints
Conditions for verification: Original records on Trial-specific exposure durations and final SBP timepoints must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Trial-specific exposure durations and final SBP timepoints is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N05 · Do the included adults share the same risks and diagnoses?

Required materials and conditions: Composition by diagnosis/baseline risk among adults with hypertension, prehypertension or metabolic risk
Conditions for verification: Original records on Composition by diagnosis/baseline risk among adults with hypertension, prehypertension or metabolic risk must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Composition by diagnosis/baseline risk among adults with hypertension, prehypertension or metabolic risk is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N06 · Was the comparator placebo or control management?

Required materials and conditions: Trial-specific placebo/control management and common-care arrangements
Conditions for verification: Original records on Trial-specific placebo/control management and common-care arrangements must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Trial-specific placebo/control management and common-care arrangements is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N07 · How do concomitant blood-pressure medicines and lifestyle management differ?

Required materials and conditions: Baseline blood-pressure medicines, changes, diet/exercise management and whether these were shared across groups
Conditions for verification: Original records on Baseline blood-pressure medicines, changes, diet/exercise management and whether these were shared across groups must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Baseline blood-pressure medicines, changes, diet/exercise management and whether these were shared across groups is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N08 · What included-material unit does the reported 17 represent?

Required materials and conditions: Review inclusion lists and study-to-report links
Conditions for verification: Original records on Review inclusion lists and study-to-report links must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Review inclusion lists and study-to-report links is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N09 · What denominator does 1,377 people represent?

Required materials and conditions: Trial-specific allocation, analysis, completion and SBP-endpoint denominators
Conditions for verification: Original records on Trial-specific allocation, analysis, completion and SBP-endpoint denominators must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Trial-specific allocation, analysis, completion and SBP-endpoint denominators is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N10 · Can review reports be linked to original-trial families?

Required materials and conditions: Included-trial identifiers and study-family links for the Hadi review
Conditions for verification: Original records on Included-trial identifiers and study-family links for the Hadi review must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Included-trial identifiers and study-family links for the Hadi review is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N11 · In which units is the overall SBP effect reported?

Required materials and conditions: Overall office-SBP WMD, units and original comparison arrangements
Conditions for verification: Original records on Overall office-SBP WMD, units and original comparison arrangements must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Overall office-SBP WMD, units and original comparison arrangements is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N12 · What is the scope of the original CI and null interpretation?

Required materials and conditions: Original 95% CI and source of SBP-importance criteria
Conditions for verification: Original records on Original 95% CI and source of SBP-importance criteria must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Original 95% CI and source of SBP-importance criteria is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N13 · How are I² and between-trial differences retained?

Required materials and conditions: Overall heterogeneity and explanations by formulation, diagnosis, dose and duration
Conditions for verification: Original records on Overall heterogeneity and explanations by formulation, diagnosis, dose and duration must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Overall heterogeneity and explanations by formulation, diagnosis, dose and duration is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N14 · Is office SBP measurement distinguished from other blood-pressure measures?

Required materials and conditions: Office-SBP equipment, repetitions, timing, assessors and original endpoint definitions
Conditions for verification: Original records on Office-SBP equipment, repetitions, timing, assessors and original endpoint definitions must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Office-SBP equipment, repetitions, timing, assessors and original endpoint definitions is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N15 · Are change values, baseline adjustment and analysis timepoints aligned?

Required materials and conditions: SBP change versus final/baseline-adjusted values and intended analysis populations
Conditions for verification: Original records on SBP change versus final/baseline-adjusted values and intended analysis populations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on SBP change versus final/baseline-adjusted values and intended analysis populations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N16 · What is known about allocation and blinding in original trials?

Required materials and conditions: Trial-specific randomization, concealment and participant/assessor blinding
Conditions for verification: Original records on Trial-specific randomization, concealment and participant/assessor blinding must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Trial-specific randomization, concealment and participant/assessor blinding is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N17 · What is known about attrition, missingness and outcome selection?

Required materials and conditions: Trial-specific attrition reasons, missing-data handling, analysis sets and selective reporting
Conditions for verification: Original records on Trial-specific attrition reasons, missing-data handling, analysis sets and selective reporting must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Trial-specific attrition reasons, missing-data handling, analysis sets and selective reporting is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N18 · Is the prespecified hierarchy of overall SBP and subgroups verified?

Required materials and conditions: Prespecified overall-SBP analysis and women/duration subgroup plans
Conditions for verification: Original records on Prespecified overall-SBP analysis and women/duration subgroup plans must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Prespecified overall-SBP analysis and women/duration subgroup plans is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N19 · Are signals in women distinguished from the overall adult effect?

Required materials and conditions: Women-subgroup effects, intervals, denominators and interaction tests
Conditions for verification: Original records on Women-subgroup effects, intervals, denominators and interaction tests must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Women-subgroup effects, intervals, denominators and interaction tests is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N20 · Are signals in the subgroup lasting at least 12 weeks distinguished from all durations?

Required materials and conditions: Trial composition, effects, intervals and denominators for durations of at least 12 weeks versus shorter durations
Conditions for verification: Original records on Trial composition, effects, intervals and denominators for durations of at least 12 weeks versus shorter durations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Trial composition, effects, intervals and denominators for durations of at least 12 weeks versus shorter durations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N21 · Is a DBP reduction kept from becoming an SBP success?

Required materials and conditions: Separate SBP/DBP endpoints, denominators and timepoints
Conditions for verification: Original records on Separate SBP/DBP endpoints, denominators and timepoints must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Separate SBP/DBP endpoints, denominators and timepoints is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N22 · Are mechanistic endpoints such as endothelial function kept separate?

Required materials and conditions: Distinguishing endothelial function/biomarkers from SBP change
Conditions for verification: Original records on Distinguishing endothelial function/biomarkers from SBP change must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Distinguishing endothelial function/biomarkers from SBP change is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N23 · Does dose-response meta-analysis establish direct dose comparisons?

Required materials and conditions: Distinguishing within-trial direct dose comparisons from between-trial dose-response models
Conditions for verification: Original records on Distinguishing within-trial direct dose comparisons from between-trial dose-response models must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Distinguishing within-trial direct dose comparisons from between-trial dose-response models is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N24 · Is independent replication within a formulation verified separately?

Required materials and conditions: Unique trials and independent teams sharing formulation, population, comparator and timepoint
Conditions for verification: Original records on Unique trials and independent teams sharing formulation, population, comparator and timepoint must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Unique trials and independent teams sharing formulation, population, comparator and timepoint is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N25 · Are clinical events and replacement of blood-pressure medicines separate questions?

Required materials and conditions: Direct material distinguishing an SBP surrogate from cardiovascular events and stopping/replacing medicines
Conditions for verification: Original records on Direct material distinguishing an SBP surrogate from cardiovascular events and stopping/replacing medicines must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Direct material distinguishing an SBP surrogate from cardiovascular events and stopping/replacing medicines is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N26 · Are four routes of company involvement kept separate?

Required materials and conditions: Review/trial funding, product support, employee authorship and COI
Conditions for verification: Original records on Review/trial funding, product support, employee authorship and COI must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Review/trial funding, product support, employee authorship and COI is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N27 · Are harm-collection methods known?

Required materials and conditions: Adverse-event definitions, active/passive collection, durations and group-specific classification
Conditions for verification: Original records on Adverse-event definitions, active/passive collection, durations and group-specific classification must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Adverse-event definitions, active/passive collection, durations and group-specific classification is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N28 · What are harm denominators and exposure durations?

Required materials and conditions: Group-specific safety denominators, actual dosing, exposure durations and harm analyses
Conditions for verification: Original records on Group-specific safety denominators, actual dosing, exposure durations and harm analyses must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Group-specific safety denominators, actual dosing, exposure durations and harm analyses is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N29 · What evidence level underlies concomitant hypotension/interaction precautions?

Required materials and conditions: Concomitant blood-pressure medicines, event timing, alternative causes and direct comparisons
Conditions for verification: Original records on Concomitant blood-pressure medicines, event timing, alternative causes and direct comparisons must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Concomitant blood-pressure medicines, event timing, alternative causes and direct comparisons is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N30 · Are long-term, rare-event and vulnerable-population harms verified?

Required materials and conditions: Harm material on long exposure, rare events and vulnerable populations
Conditions for verification: Original records on Harm material on long exposure, rare events and vulnerable populations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Harm material on long exposure, rare events and vulnerable populations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N31 · Is actual reading scope distinguished from original-source links?

Required materials and conditions: Distinguishing stored summary, abstract, full text, registration and protocols/SAPs
Conditions for verification: Original records on Distinguishing stored summary, abstract, full text, registration and protocols/SAPs must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Distinguishing stored summary, abstract, full text, registration and protocols/SAPs is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N32 · How are historical English corrections and remaining generic wording retained?

Required materials and conditions: Original Korean/English material and targets/limits of the 2026-09-14 correction
Conditions for verification: Original records on Original Korean/English material and targets/limits of the 2026-09-14 correction must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Original Korean/English material and targets/limits of the 2026-09-14 correction is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

N33 · Are original grade, axes, dates and new preparation distinguished?

Required materials and conditions: Original D30, Caution, axes, evidence date and correction
Conditions for verification: Original records on Original D30, Caution, axes, evidence date and correction must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Original D30, Caution, axes, evidence date and correction is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

What the statuses mean

Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete: Review of existing content remains incomplete.
Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable: Used only with an application exception and reason based on the question scope.
Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-24 · Public page/material version 1.0

The public view and materials were prepared from the existing 33 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-08) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which systolic-blood-pressure question is addressed?

Current findings: The original question concerns systolic-blood-pressure reduction in adults with metabolic risk, with office SBP as the endpoint. Medicine replacement and other endpoints are excluded.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original eligibility criteria and endpoint tables specifying the same population, formulation, comparator and office SBP are needed.
Required materials and conditions: Oral curcumin/curcuminoid supplementation and office SBP change in adults with metabolic risk
Materials to obtain first: Original eligibility criteria and endpoint tables specifying the same population, formulation, comparator and office SBP are needed.
Further research: Material needed: Original eligibility criteria and endpoint tables specifying the same population, formulation, comparator and office SBP are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Oral curcumin/curcuminoid supplementation and office SBP change in adults with metabolic risk must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Oral curcumin/curcuminoid supplementation and office SBP change in adults with metabolic risk is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N02 · Which formulations were pooled, and do they match individual products?

Current findings: The retained formulation is mixed oral products. The product notes do not treat conventional curcumin, nano/micellar, phytosomal, piperine-combination and topical products as equivalent.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Actual formulations, absorption enhancers, standardized amounts and product information for included trials are unavailable; efficacy or equivalence of an individual product is not established.
Required materials and conditions: Original-trial tables separating conventional curcumin, nano/micellar, phytosomal and piperine-combination formulations
Materials to obtain first: Actual formulations, absorption enhancers, standardized amounts and product information for included trials are unavailable; efficacy or equivalence of an individual product is not established.
Further research: Material needed: Actual formulations, absorption enhancers, standardized amounts and product information for included trials are unavailable; efficacy or equivalence of an individual product is not established. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Original-trial tables separating conventional curcumin, nano/micellar, phytosomal and piperine-combination formulations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original-trial tables separating conventional curcumin, nano/micellar, phytosomal and piperine-combination formulations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N03 · Which doses and administration frequencies were compared?

Current findings: Doses vary by trial. Representative doses, conversions of total product amounts to active amounts and recommended doses are not generated.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original amount/dose/adherence tables are needed. The phrase dose response in the meta-analysis title does not establish an optimum dose.
Required materials and conditions: Trial-specific active-curcumin/curcuminoid amounts, total product amounts and administration frequencies
Materials to obtain first: Original amount/dose/adherence tables are needed. The phrase dose response in the meta-analysis title does not establish an optimum dose.
Further research: Material needed: Original amount/dose/adherence tables are needed. The phrase dose response in the meta-analysis title does not establish an optimum dose. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Trial-specific active-curcumin/curcuminoid amounts, total product amounts and administration frequencies must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial-specific active-curcumin/curcuminoid amounts, total product amounts and administration frequencies is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N04 · How are duration and outcome timepoints arranged?

Current findings: Durations vary by trial, with some at least 12 weeks. The overall pooled estimate is not labeled as an estimate restricted to trials lasting at least 12 weeks.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Trial-specific durations, measurement schedules and original extracted values by duration group are needed. Long-term persistence and post-discontinuation effects remain unverified.
Required materials and conditions: Trial-specific exposure durations and final SBP timepoints
Materials to obtain first: Trial-specific durations, measurement schedules and original extracted values by duration group are needed. Long-term persistence and post-discontinuation effects remain unverified.
Further research: Material needed: Trial-specific durations, measurement schedules and original extracted values by duration group are needed. Long-term persistence and post-discontinuation effects remain unverified. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Trial-specific exposure durations and final SBP timepoints must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial-specific exposure durations and final SBP timepoints is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N05 · Do the included adults share the same risks and diagnoses?

Current findings: The population includes adults with hypertension, prehypertension or metabolic risk. It is not relabeled as a single hypertensive population.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original-trial tables by diagnosis, baseline SBP, age, comorbidities and eligibility/exclusion criteria are needed.
Required materials and conditions: Composition by diagnosis/baseline risk among adults with hypertension, prehypertension or metabolic risk
Materials to obtain first: Original-trial tables by diagnosis, baseline SBP, age, comorbidities and eligibility/exclusion criteria are needed.
Further research: Material needed: Original-trial tables by diagnosis, baseline SBP, age, comorbidities and eligibility/exclusion criteria are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Composition by diagnosis/baseline risk among adults with hypertension, prehypertension or metabolic risk must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Composition by diagnosis/baseline risk among adults with hypertension, prehypertension or metabolic risk is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N06 · Was the comparator placebo or control management?

Current findings: The comparator is placebo or control management. Identical placebo and lifestyle-care arrangements across all trials are not established.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Trial-specific material separating placebo ingredients, blinding, shared dietary/exercise management and additional interventions is needed.
Required materials and conditions: Trial-specific placebo/control management and common-care arrangements
Materials to obtain first: Trial-specific material separating placebo ingredients, blinding, shared dietary/exercise management and additional interventions is needed.
Further research: Material needed: Trial-specific material separating placebo ingredients, blinding, shared dietary/exercise management and additional interventions is needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Trial-specific placebo/control management and common-care arrangements must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial-specific placebo/control management and common-care arrangements is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N07 · How do concomitant blood-pressure medicines and lifestyle management differ?

Current findings: The original precaution says curcumin does not replace blood-pressure medicines and possible hypotension/interactions during concomitant use require individual review. Included-trial co-treatment arrangements are absent from the summary.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original-trial records on medicine doses/changes, lifestyle management, rescue medicines and adherence are needed. Efficacy is not separated as the supplement-only effect.
Required materials and conditions: Baseline blood-pressure medicines, changes, diet/exercise management and whether these were shared across groups
Materials to obtain first: Original-trial records on medicine doses/changes, lifestyle management, rescue medicines and adherence are needed. Efficacy is not separated as the supplement-only effect.
Further research: Material needed: Original-trial records on medicine doses/changes, lifestyle management, rescue medicines and adherence are needed. Efficacy is not separated as the supplement-only effect. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Baseline blood-pressure medicines, changes, diet/exercise management and whether these were shared across groups must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Baseline blood-pressure medicines, changes, diet/exercise management and whether these were shared across groups is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N08 · What included-material unit does the reported 17 represent?

Current findings: The research description says mean differences from 17 trials were pooled; the evidence scope says 17 studies and 1,377 people. Original wording is retained without certifying 17 unique trials here.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Links among included articles, registrations, duplicate reports and multiple arms are needed. Reported scope remains distinct from verified unique-trial counts.
Required materials and conditions: Review inclusion lists and study-to-report links
Materials to obtain first: Links among included articles, registrations, duplicate reports and multiple arms are needed. Reported scope remains distinct from verified unique-trial counts.
Further research: Material needed: Links among included articles, registrations, duplicate reports and multiple arms are needed. Reported scope remains distinct from verified unique-trial counts. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Review inclusion lists and study-to-report links must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Review inclusion lists and study-to-report links is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N09 · What denominator does 1,377 people represent?

Current findings: 1,377 people is the original reported scope. Group-specific allocation, analysis, completion and SBP analysis denominators are not generated. Unique-participant totals remain unverified.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Trial/group-specific randomized, analyzed and completed denominators, with participant-overlap information, are needed. The final unique-participant total remains null.
Required materials and conditions: Trial-specific allocation, analysis, completion and SBP-endpoint denominators
Materials to obtain first: Trial/group-specific randomized, analyzed and completed denominators, with participant-overlap information, are needed. The final unique-participant total remains null.
Further research: Material needed: Trial/group-specific randomized, analyzed and completed denominators, with participant-overlap information, are needed. The final unique-participant total remains null. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Trial-specific allocation, analysis, completion and SBP-endpoint denominators must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial-specific allocation, analysis, completion and SBP-endpoint denominators is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N10 · Can review reports be linked to original-trial families?

Current findings: The structured report is a single review by Hadi and colleagues. One review report remains distinct from counts of original trials and independent teams. Original-trial families/overlap remain unverified.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Articles, registrations and additional reports for included trials, with the review extraction table, are needed. Shared trials and reused samples remain unverified.
Required materials and conditions: Included-trial identifiers and study-family links for the Hadi review
Materials to obtain first: Articles, registrations and additional reports for included trials, with the review extraction table, are needed. Shared trials and reused samples remain unverified.
Further research: Material needed: Articles, registrations and additional reports for included trials, with the review extraction table, are needed. Shared trials and reused samples remain unverified. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Included-trial identifiers and study-family links for the Hadi review must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Included-trial identifiers and study-family links for the Hadi review is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N11 · In which units is the overall SBP effect reported?

Current findings: The overall result is WMD −0.06 mmHg, 95% CI −0.62 to 0.50, P=.85; I²=44.2%. The numbers are retained without new conversion or pooling.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original pooling tables, extracted values, weights, analysis models and change/final-value distinctions are needed. New estimates, conversions and clinical numerical calculations are not produced.
Required materials and conditions: Overall office-SBP WMD, units and original comparison arrangements
Materials to obtain first: Original pooling tables, extracted values, weights, analysis models and change/final-value distinctions are needed. New estimates, conversions and clinical numerical calculations are not produced.
Further research: Material needed: Original pooling tables, extracted values, weights, analysis models and change/final-value distinctions are needed. New estimates, conversions and clinical numerical calculations are not produced. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Overall office-SBP WMD, units and original comparison arrangements must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Overall office-SBP WMD, units and original comparison arrangements is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N12 · What is the scope of the original CI and null interpretation?

Current findings: The original reader answer describes a clear null result, and the key rationale says the entire CI lies within 1 mmHg. Those original verdict statements are retained without new equivalence/null certification.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Unread original analysis tables and prespecified importance/equivalence criteria are needed. Equivalence for all formulations/populations or a new D verdict is not certified here.
Required materials and conditions: Original 95% CI and source of SBP-importance criteria
Materials to obtain first: Unread original analysis tables and prespecified importance/equivalence criteria are needed. Equivalence for all formulations/populations or a new D verdict is not certified here.
Further research: Material needed: Unread original analysis tables and prespecified importance/equivalence criteria are needed. Equivalence for all formulations/populations or a new D verdict is not certified here. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Original 95% CI and source of SBP-importance criteria must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original 95% CI and source of SBP-importance criteria is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N13 · How are I² and between-trial differences retained?

Current findings: I²=44.2% is an original value. The counterview retains possible post hoc subgrouping and heterogeneity. This number does not establish identical formulations, populations or durations.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original heterogeneity tables, extracted values, model/sensitivity analyses and prediction intervals are needed. I² alone does not establish equal results across formulations.
Required materials and conditions: Overall heterogeneity and explanations by formulation, diagnosis, dose and duration
Materials to obtain first: Original heterogeneity tables, extracted values, model/sensitivity analyses and prediction intervals are needed. I² alone does not establish equal results across formulations.
Further research: Material needed: Original heterogeneity tables, extracted values, model/sensitivity analyses and prediction intervals are needed. I² alone does not establish equal results across formulations. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Overall heterogeneity and explanations by formulation, diagnosis, dose and duration must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Overall heterogeneity and explanations by formulation, diagnosis, dose and duration is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N14 · Is office SBP measurement distinguished from other blood-pressure measures?

Current findings: The selected endpoint is office systolic-blood-pressure change. It is not replaced with ambulatory/home blood pressure or DBP.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Trial-specific measurement procedures, assessor blinding and repeated-measurement/averaging rules are needed.
Required materials and conditions: Office-SBP equipment, repetitions, timing, assessors and original endpoint definitions
Materials to obtain first: Trial-specific measurement procedures, assessor blinding and repeated-measurement/averaging rules are needed.
Further research: Material needed: Trial-specific measurement procedures, assessor blinding and repeated-measurement/averaging rules are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Office-SBP equipment, repetitions, timing, assessors and original endpoint definitions must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Office-SBP equipment, repetitions, timing, assessors and original endpoint definitions is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N15 · Are change values, baseline adjustment and analysis timepoints aligned?

Current findings: The selected endpoint describes SBP change, while the research description says mean differences were pooled. Detailed arrangements for change/final values, adjustment and timepoint selection remain unverified.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original extraction tables, analysis plans, baseline values, variance handling, endpoint timepoints and duplicate-timepoint selection rules are needed.
Required materials and conditions: SBP change versus final/baseline-adjusted values and intended analysis populations
Materials to obtain first: Original extraction tables, analysis plans, baseline values, variance handling, endpoint timepoints and duplicate-timepoint selection rules are needed.
Further research: Material needed: Original extraction tables, analysis plans, baseline values, variance handling, endpoint timepoints and duplicate-timepoint selection rules are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on SBP change versus final/baseline-adjusted values and intended analysis populations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on SBP change versus final/baseline-adjusted values and intended analysis populations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N16 · What is known about allocation and blinding in original trials?

Current findings: The retained design is a systematic review and dose-response meta-analysis. Adequacy of original-trial allocation, concealment and blinding is not judged here.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original-trial methods, registration/protocols and the review's individual risk-assessment bases are needed. Official RoB2 findings are not generated.
Required materials and conditions: Trial-specific randomization, concealment and participant/assessor blinding
Materials to obtain first: Original-trial methods, registration/protocols and the review's individual risk-assessment bases are needed. Official RoB2 findings are not generated.
Further research: Material needed: Original-trial methods, registration/protocols and the review's individual risk-assessment bases are needed. Official RoB2 findings are not generated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Trial-specific randomization, concealment and participant/assessor blinding must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial-specific randomization, concealment and participant/assessor blinding is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N17 · What is known about attrition, missingness and outcome selection?

Current findings: The stored sample description gives overall scope without specific group-level attrition, missingness or analysis-exclusion reasons. Unread original material is not relabeled as having no missingness.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Group flow diagrams, analysis denominators, missing-data handling, all SBP timepoints and registration-to-report comparisons are needed.
Required materials and conditions: Trial-specific attrition reasons, missing-data handling, analysis sets and selective reporting
Materials to obtain first: Group flow diagrams, analysis denominators, missing-data handling, all SBP timepoints and registration-to-report comparisons are needed.
Further research: Material needed: Group flow diagrams, analysis denominators, missing-data handling, all SBP timepoints and registration-to-report comparisons are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Trial-specific attrition reasons, missing-data handling, analysis sets and selective reporting must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial-specific attrition reasons, missing-data handling, analysis sets and selective reporting is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N18 · Is the prespecified hierarchy of overall SBP and subgroups verified?

Current findings: The original explanation says signals in women or trials lasting at least 12 weeks do not replace the overall SBP main result. The counterview retains possible post hoc subgrouping. Prespecification remains unverified.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Review registration, protocols/SAPs with primary-endpoint/subgroup/multiplicity plans, and original-trial prespecified endpoint hierarchies, are needed.
Required materials and conditions: Prespecified overall-SBP analysis and women/duration subgroup plans
Materials to obtain first: Review registration, protocols/SAPs with primary-endpoint/subgroup/multiplicity plans, and original-trial prespecified endpoint hierarchies, are needed.
Further research: Material needed: Review registration, protocols/SAPs with primary-endpoint/subgroup/multiplicity plans, and original-trial prespecified endpoint hierarchies, are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Prespecified overall-SBP analysis and women/duration subgroup plans must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Prespecified overall-SBP analysis and women/duration subgroup plans is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N19 · Are signals in women distinguished from the overall adult effect?

Current findings: The original explanation mentions a signal in women. The structured evidence contains no women-only effect, CI or denominator. The overall WMD is not copied as an individual women-subgroup estimate.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original sex-subgroup tables, prespecification, interactions and included-trial counts are needed. The overall −0.06 mmHg is not copied as a women-only estimate.
Required materials and conditions: Women-subgroup effects, intervals, denominators and interaction tests
Materials to obtain first: Original sex-subgroup tables, prespecification, interactions and included-trial counts are needed. The overall −0.06 mmHg is not copied as a women-only estimate.
Further research: Material needed: Original sex-subgroup tables, prespecification, interactions and included-trial counts are needed. The overall −0.06 mmHg is not copied as a women-only estimate. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Women-subgroup effects, intervals, denominators and interaction tests must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Women-subgroup effects, intervals, denominators and interaction tests is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N20 · Are signals in the subgroup lasting at least 12 weeks distinguished from all durations?

Current findings: Some durations of at least 12 weeks and the corresponding subgroup signal are described. The structured overall result is not relabeled as an individual long-duration estimate or persistent effect.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original duration-group tables, prespecification, other formulation/population differences accompanying duration, and interaction material are needed.
Required materials and conditions: Trial composition, effects, intervals and denominators for durations of at least 12 weeks versus shorter durations
Materials to obtain first: Original duration-group tables, prespecification, other formulation/population differences accompanying duration, and interaction material are needed.
Further research: Material needed: Original duration-group tables, prespecification, other formulation/population differences accompanying duration, and interaction material are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Trial composition, effects, intervals and denominators for durations of at least 12 weeks versus shorter durations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial composition, effects, intervals and denominators for durations of at least 12 weeks versus shorter durations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N21 · Is a DBP reduction kept from becoming an SBP success?

Current findings: Possible DBP reductions are a separate-analysis narrative in the counterview; the verdict-scope note says only SBP was graded. DBP results are not transferred into SBP success.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original DBP results and endpoint hierarchy address a separate question. DBP estimates and grades are not merged into these SBP rows.
Required materials and conditions: Separate SBP/DBP endpoints, denominators and timepoints
Materials to obtain first: Original DBP results and endpoint hierarchy address a separate question. DBP estimates and grades are not merged into these SBP rows.
Further research: Material needed: Original DBP results and endpoint hierarchy address a separate question. DBP estimates and grades are not merged into these SBP rows. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Separate SBP/DBP endpoints, denominators and timepoints must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Separate SBP/DBP endpoints, denominators and timepoints is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N22 · Are mechanistic endpoints such as endothelial function kept separate?

Current findings: The verdict-scope note separates DBP and endothelial function. Endothelial/mechanistic improvement is not relabeled as this office-SBP result or a clinical-event effect.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Separate definitions, trials and original results for mechanistic endpoints are needed. Mechanistic improvement is not relabeled as an SBP or clinical-event effect.
Required materials and conditions: Distinguishing endothelial function/biomarkers from SBP change
Materials to obtain first: Separate definitions, trials and original results for mechanistic endpoints are needed. Mechanistic improvement is not relabeled as an SBP or clinical-event effect.
Further research: Material needed: Separate definitions, trials and original results for mechanistic endpoints are needed. Mechanistic improvement is not relabeled as an SBP or clinical-event effect. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing endothelial function/biomarkers from SBP change must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing endothelial function/biomarkers from SBP change is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N23 · Does dose-response meta-analysis establish direct dose comparisons?

Current findings: The original design is a dose-response meta-analysis. Actual direct dose-comparison and optimum-dose results are absent from the stored summary. The name dose response does not establish a recommended amount.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Trial-specific doses, effects, covariates, model/sensitivity analyses and direct dose trials are needed.
Required materials and conditions: Distinguishing within-trial direct dose comparisons from between-trial dose-response models
Materials to obtain first: Trial-specific doses, effects, covariates, model/sensitivity analyses and direct dose trials are needed.
Further research: Material needed: Trial-specific doses, effects, covariates, model/sensitivity analyses and direct dose trials are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing within-trial direct dose comparisons from between-trial dose-response models must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing within-trial direct dose comparisons from between-trial dose-response models is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N24 · Is independent replication within a formulation verified separately?

Current findings: The original grading rationale describes a precise synthesis across multiple independent studies. Included trials and independent teams are not certified here or promoted into formulation-specific replication.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original included-trial links, funding/authors and product information are needed. Mixed-formulation pooling alone does not establish independent replication for a particular formulation.
Required materials and conditions: Unique trials and independent teams sharing formulation, population, comparator and timepoint
Materials to obtain first: Original included-trial links, funding/authors and product information are needed. Mixed-formulation pooling alone does not establish independent replication for a particular formulation.
Further research: Material needed: Original included-trial links, funding/authors and product information are needed. Mixed-formulation pooling alone does not establish independent replication for a particular formulation. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Unique trials and independent teams sharing formulation, population, comparator and timepoint must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Unique trials and independent teams sharing formulation, population, comparator and timepoint is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N25 · Are clinical events and replacement of blood-pressure medicines separate questions?

Current findings: The advertising limits say claims of replacing blood-pressure medicines or treating hypertension contradict the evidence. The current endpoint is SBP change, not direct results on clinical events or medicine replacement.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Direct research on cardiovascular events or stopping/replacing medicines is not verified in this material. Prevention, treatment or replacement effects are not added here.
Required materials and conditions: Direct material distinguishing an SBP surrogate from cardiovascular events and stopping/replacing medicines
Materials to obtain first: Direct research on cardiovascular events or stopping/replacing medicines is not verified in this material. Prevention, treatment or replacement effects are not added here.
Further research: Material needed: Direct research on cardiovascular events or stopping/replacing medicines is not verified in this material. Prevention, treatment or replacement effects are not added here. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Direct material distinguishing an SBP surrogate from cardiovascular events and stopping/replacing medicines must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Direct material distinguishing an SBP surrogate from cardiovascular events and stopping/replacing medicines is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N26 · Are four routes of company involvement kept separate?

Current findings: The funding description says non-commercial researchers and mixed funding of included trials. The English funding wording is a generic statement distinguishing involvement routes. This is not relabeled as absence of company involvement in all trials.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original funding, product provision, author affiliations and COI disclosures for the review and original trials are needed. Non-commercial researchers do not establish absence of company involvement in every trial.
Required materials and conditions: Review/trial funding, product support, employee authorship and COI
Materials to obtain first: Original funding, product provision, author affiliations and COI disclosures for the review and original trials are needed. Non-commercial researchers do not establish absence of company involvement in every trial.
Further research: Material needed: Original funding, product provision, author affiliations and COI disclosures for the review and original trials are needed. Non-commercial researchers do not establish absence of company involvement in every trial. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Review/trial funding, product support, employee authorship and COI must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Review/trial funding, product support, employee authorship and COI is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N27 · Are harm-collection methods known?

Current findings: The original safety detail retains caution and possible hypotension/interactions during concomitant use. Harm-collection methods and event tables are not preserved in detail.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Included-trial harm methods, event tables, withdrawals and severity records are needed. Unread material is not labeled as no harm.
Required materials and conditions: Adverse-event definitions, active/passive collection, durations and group-specific classification
Materials to obtain first: Included-trial harm methods, event tables, withdrawals and severity records are needed. Unread material is not labeled as no harm.
Further research: Material needed: Included-trial harm methods, event tables, withdrawals and severity records are needed. Unread material is not labeled as no harm. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Adverse-event definitions, active/passive collection, durations and group-specific classification must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Adverse-event definitions, active/passive collection, durations and group-specific classification is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N28 · What are harm denominators and exposure durations?

Current findings: 1,377 people describes the evidence scope, not a safety denominator. Durations also vary by trial. Group-specific event counts, exposure and harm denominators remain unverified.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Safety sets, exposure amounts/time, group-specific event counts and discontinuation records are needed. Incidence is not calculated.
Required materials and conditions: Group-specific safety denominators, actual dosing, exposure durations and harm analyses
Materials to obtain first: Safety sets, exposure amounts/time, group-specific event counts and discontinuation records are needed. Incidence is not calculated.
Further research: Material needed: Safety sets, exposure amounts/time, group-specific event counts and discontinuation records are needed. Incidence is not calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Group-specific safety denominators, actual dosing, exposure durations and harm analyses must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Group-specific safety denominators, actual dosing, exposure durations and harm analyses is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N29 · What evidence level underlies concomitant hypotension/interaction precautions?

Current findings: The original wording is a precaution requiring individual review of concomitant use. It is not actual hypotension incidence, established causation or a direct interaction comparison.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Medicine types/changes, event timing, comparators, rechallenge and alternative-cause material are needed.
Required materials and conditions: Concomitant blood-pressure medicines, event timing, alternative causes and direct comparisons
Materials to obtain first: Medicine types/changes, event timing, comparators, rechallenge and alternative-cause material are needed.
Further research: Material needed: Medicine types/changes, event timing, comparators, rechallenge and alternative-cause material are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Concomitant blood-pressure medicines, event timing, alternative causes and direct comparisons must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Concomitant blood-pressure medicines, event timing, alternative causes and direct comparisons is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N30 · Are long-term, rare-event and vulnerable-population harms verified?

Current findings: Mixed durations and precautions alone do not certify long-term, rare-event or vulnerable-population safety, or independent harm replication. Corresponding original material remains unverified.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Long-term follow-up, vulnerable populations, independent harm reports and exposure/denominators are needed. These harms are not newly investigated or established here.
Required materials and conditions: Harm material on long exposure, rare events and vulnerable populations
Materials to obtain first: Long-term follow-up, vulnerable populations, independent harm reports and exposure/denominators are needed. These harms are not newly investigated or established here.
Further research: Material needed: Long-term follow-up, vulnerable populations, independent harm reports and exposure/denominators are needed. These harms are not newly investigated or established here. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Harm material on long exposure, rare events and vulnerable populations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Harm material on long exposure, rare events and vulnerable populations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N31 · Is actual reading scope distinguished from original-source links?

Current findings: The full stored record was read for preparation. The original PubMed URL is linked, while external abstracts, full texts, registration and protocols/SAPs remain unread in this work.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: External original material remains unread until acquired and reviewed. A URL does not establish reading, accessibility or fulfillment of conditions.
Required materials and conditions: Distinguishing stored summary, abstract, full text, registration and protocols/SAPs
Materials to obtain first: External original material remains unread until acquired and reviewed. A URL does not establish reading, accessibility or fulfillment of conditions.
Further research: Material needed: External original material remains unread until acquired and reviewed. A URL does not establish reading, accessibility or fulfillment of conditions. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing stored summary, abstract, full text, registration and protocols/SAPs must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing stored summary, abstract, full text, registration and protocols/SAPs is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N32 · How are historical English corrections and remaining generic wording retained?

Current findings: The correction records replacement of English placeholders while retaining grade, score, citations and evidence date. Remaining generic English sample, funding and result wording is preserved in the original; historical correction targets and external English material are not newly reviewed.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Historical corrected English and external papers are not newly compared here. The original correction is not relabeled as completed current content QA or certified original-paper reading.
Required materials and conditions: Original Korean/English material and targets/limits of the 2026-09-14 correction
Materials to obtain first: Historical corrected English and external papers are not newly compared here. The original correction is not relabeled as completed current content QA or certified original-paper reading.
Further research: Material needed: Historical corrected English and external papers are not newly compared here. The original correction is not relabeled as completed current content QA or certified original-paper reading. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Original Korean/English material and targets/limits of the 2026-09-14 correction must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original Korean/English material and targets/limits of the 2026-09-14 correction is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01

N33 · Are original grade, axes, dates and new preparation distinguished?

Current findings: The original D/30/Caution, evidence date 2026-09-08, axes and correction are retained. Preparation is not a new efficacy grade or independent clinical certification; the original date is not relabeled as a current search-end or external-reading date.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: New material and verdict changes are handled through separate review and events. The original verdict date is not relabeled as a current search-end or external-reading date.
Required materials and conditions: Original D30, Caution, axes, evidence date and correction
Materials to obtain first: New material and verdict changes are handled through separate review and events. The original verdict date is not relabeled as a current search-end or external-reading date.
Further research: Material needed: New material and verdict changes are handled through separate review and events. The original verdict date is not relabeled as a current search-end or external-reading date. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diagnoses, doses, durations, measurement, timepoints, denominators, overlap, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Original D30, Caution, axes, evidence date and correction must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original D30, Caution, axes, evidence date and correction is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.

Related sources R01